Pharmacogenomics of drugs used to treat brain disorders
- 17 March 2020
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Precision Medicine and Drug Development
- Vol. 5 (3), 181-234
- https://doi.org/10.1080/23808993.2020.1738217
Abstract
Introduction: Neuropsychiatric disorders (NPDs) (neurodevelopmental, mental, neurodegenerative, neurotoxic, complex disorders) are the third major problem of health in developed countries. About 10-20% of direct costs are attributed to pharmacological treatment; however, drug effectiveness is lower than 30% in most NPDs. Pharmacogenomics accounts for 60-90% variability in pharmacokinetics and pharmacodynamics. Areas covered: Main areas covered include (i) organization of the pharmacogenetic machinery (pathogenic, mechanistic, metabolic, transporter, pleiotropic genes); (ii) pharmacogenomics of antidepressants, antipsychotics, anxiolytics, antiepileptics, anti-Alzheimer, anti-Parkinson, and anti-stroke drugs; and (iii) adverse drug reactions and pharmaco-resistance. Expert commentary: The pharmacogenomics of NPDs is still primitive, but sufficient to help physicians to optimize pharmacological treatment by reducing ADRs (extrapyramidal symptoms, tardive dyskinesia, neurotoxicity, cerebrovascular damage) and unnecessary costs. Over 50% of psychotropic drugs are incorrectly prescribed. CYP enzymes participate in the metabolism of over 90% of drugs for the treatment of NPDs. Only 20% of the population is potentially extensive metabolizer for 80% of current psychotropic agents. Consequently, the introduction of pharmacogenomic procedures in the clinical setting is an urgent need for improving drug efficacy and safety.Keywords
Funding Information
- EuroEspes Biomedical Research Center and IABRA
- International Agency for Brain Research and Aging
This publication has 264 references indexed in Scilit:
- Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in XinjiangLipids in Health and Disease, 2013
- The CYP1A2 –163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patientsPsychiatry Research, 2013
- Association of SNPs of CD40 Gene with Multiple Sclerosis in RussiansPLOS ONE, 2013
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer's PatientsCNS Neuroscience & Therapeutics, 2012
- The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced MyopathyClinical Pharmacology & Therapeutics, 2012
- Genetics of Tardive DyskinesiaInternational Review of Neurobiology, 2011
- Care homes' use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older peopleQuality and Safety in Health Care, 2009
- Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer diseaseNeurology, 2009
- Individual and Societal Effects of Mental Disorders on Earnings in the United States: Results From the National Comorbidity Survey ReplicationAmerican Journal of Psychiatry, 2008